Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Post-graduate Program in Endocrinology, Medicine School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Front Endocrinol (Lausanne). 2021 Oct 19;12:759835. doi: 10.3389/fendo.2021.759835. eCollection 2021.
Polycystic ovary syndrome (PCOS) is an endocrine disorder that commonly affects women of childbearing age and has been associated with metabolic and reproductive abnormalities. Only a few studies have investigated metabolic traits in women with PCOS in Latin America. Therefore, we conducted a systematic review to provide an overview of the available evidence on the metabolic profile of Latin American women with PCOS.
We searched PubMed, Cochrane Central Register of Controlled Trials, and Embase databases for cross-sectional, case-control, or cohort studies focusing on populations of countries in South and Central America and Mexico, published until October 31, 2019. We selected studies that reported the diagnostic criteria for PCOS. In the absence of a control group, we included studies if they reported relevant metabolic data.
The initial search yielded 4878 records, of which 41 studies were included in the systematic review. Sample sizes ranged from 10 to 288 in PCOS groups and from 10 to 1500 in control groups. The prevalence of phenotypes A and B (classic PCOS) ranged from 65.8% to 87.5% as reported in studies from Argentina, Brazil, and Chile. Metabolic syndrome ranged from 33.3% to 44.0% for phenotype A, from 15.0% to 58.0% for phenotype B, from 11.9% to 36.0% for phenotype C, and from 14.2% to 66.0% for phenotype D. Women with PCOS had higher body mass index, waist circumference, blood pressure, glucose, and homeostasis model assessment index as well as a more adverse lipid profile than those without PCOS.
Evidence from the present systematic review suggests that anthropometric and metabolic profiles are worse in women with PCOS who live in different Latin American countries than in women without PCOS living in the same region. Additional studies assessing metabolic comorbidities, such as diabetes, and distinct PCOS phenotypes in different Latin American countries are warranted and may produce invaluable information for primary and secondary prevention of PCOS in the region. This systematic review was registered with PROSPERO under number CRD42016038537.
PROSPERO, identifier CRD42016038537.
多囊卵巢综合征（PCOS）是一种常见于育龄妇女的内分泌疾病，与代谢和生殖异常有关。仅有少数研究调查了拉丁美洲妇女的 PCOS 代谢特征。因此，我们进行了一项系统评价，以提供关于拉丁美洲妇女 PCOS 代谢特征的现有证据概述。
我们检索了 PubMed、Cochrane 对照试验中心注册库和 Embase 数据库，以获取关注南美洲和中美洲以及墨西哥国家人群的横断面、病例对照或队列研究，检索时间截至 2019 年 10 月 31 日。我们选择了报告 PCOS 诊断标准的研究。如果没有对照组，我们纳入了报告了相关代谢数据的研究。
最初的检索得到了 4878 条记录，其中 41 项研究被纳入系统评价。PCOS 组的样本量范围为 10 至 288，对照组的样本量范围为 10 至 1500。阿根廷、巴西和智利的研究报告经典 PCOS（表型 A 和 B）的患病率为 65.8%至 87.5%。表型 A 的代谢综合征患病率为 33.3%至 44.0%，表型 B 为 15.0%至 58.0%，表型 C 为 11.9%至 36.0%，表型 D 为 14.2%至 66.0%。与无 PCOS 的妇女相比，PCOS 妇女的体重指数、腰围、血压、血糖和稳态模型评估指数更高，血脂谱更差。
本系统评价的证据表明，生活在不同拉丁美洲国家的 PCOS 妇女的人体测量和代谢特征比生活在同一地区的无 PCOS 妇女更差。需要在不同的拉丁美洲国家评估代谢合并症（如糖尿病）和不同的 PCOS 表型，这可能为该地区 PCOS 的一级和二级预防提供宝贵的信息。本系统评价已在 PROSPERO 注册，注册号为 CRD42016038537。
PROSPERO，注册号 CRD42016038537。
